Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | WDR5 | P61964 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | TOP1 | P11387 | 1/20 | 0.33 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.33 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.33 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1179621 | 0.83 | HPGD (0.44) | HPGDSMN1; SMN2L3MBTL1ALDH1A1ATM | |
| SCHEMBL1178940 | 0.75 | POLB (0.39) | HPGDSMN1; SMN2L3MBTL1ALDH1A1ATM | |
| SCHEMBL1178125 | 0.74 | POLB (0.46) | SMN1; SMN2L3MBTL1ALDH1A1ATMTSHR | |
| SCHEMBL1178471 | 0.72 | MEN1 (0.34) | HPGDL3MBTL1ALDH1A1POLBMAPT | |
| SCHEMBL1178410 | 0.69 | ATM (0.41) | HPGDSMN1; SMN2ALDH1A1ATMTSHR | |
| SCHEMBL1180626 | 0.69 | POLB (0.39) | HPGDSMN1; SMN2L3MBTL1ALDH1A1ATM | |
| SCHEMBL10209952 | 0.67 | BRD4 (0.37) | HPGDSMN1; SMN2L3MBTL1ALDH1A1MAPT | |
| SCHEMBL6912399 | 0.67 | SLC6A4 (0.45) | — | |
| SCHEMBL11348223 | 0.66 | MAPK1 (0.58) | HPGDSMN1; SMN2ALDH1A1POLBMAPT | |
| Hydrochloric Acid SCHEMBL4206022 | 0.65 | LMNA (0.47) | SMN1; SMN2L3MBTL1ATMTSHRPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2459542-B1 | Substituted N-benzyl-4,5-dihydrooxazol-2-amines useful as selective alpha 2B/2C receptor agonists | ALLERGAN INC (US) | 2014-10-29 | — | — | EP | disclosed |
| EP-2459542-B1 | Substituted N-benzyl-4,5-dihydrooxazol-2-amines useful as selective alpha 2B/2C receptor agonists | ALLERGAN INC (US) | 2014-10-29 | — | — | EP | disclosed |
| US-8329918-B2 | Selective alpha 2B/2C agonists | ALLERGAN INC. (US) | 2012-12-11 | — | — | US | disclosed |
| US-8329918-B2 | Selective alpha 2B/2C agonists | ALLERGAN INC. (US) | 2012-12-11 | — | — | US | disclosed |
| US-8329918-B2 | Selective alpha 2B/2C agonists | ALLERGAN INC. (US) | 2012-12-11 | — | — | US | disclosed |
| EP-2459542-A1 | SELECTIVE ALPHA 2B/2C AGONISTS | Allergan, Inc. (US) | 2012-06-06 | — | — | EP | disclosed |
| US-20110028523-A1 | Selective Alpha 2B/2C Agonists | ALLERGAN, INC. (US) | 2011-02-03 | — | — | US | disclosed |
| US-20110028523-A1 | Selective Alpha 2B/2C Agonists | ALLERGAN, INC. (US) | 2011-02-03 | — | — | US | disclosed |
| US-20110028523-A1 | Selective Alpha 2B/2C Agonists | ALLERGAN, INC. (US) | 2011-02-03 | — | — | US | disclosed |
| WO-2011014332-A1 | SELECTIVE ALPHA 2B/2C AGONISTS | ALLERGAN, INC. (US) | 2011-02-03 | — | — | WO | disclosed |
| WO-2011014332-A1 | SELECTIVE ALPHA 2B/2C AGONISTS | ALLERGAN, INC. (US) | 2011-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028523-A1 | Selective Alpha 2B/2C Agonists | ADRA2C, ADRA2B, ADRB2 | HPGD 1442/4885SMN1; SMN2 1092/4885L3MBTL1 4270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.